Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00027404 · ClinicalTrials.gov registry record · NA
Study of Fluoxetine in Adults With Autistic Disorder
A NA study, sponsored by Icahn School of Medicine at Mount Sinai.
- Completed
- Registry status
- NA
- Development phase
- 48
- Enrollment target
NCT00027404 is a NA study that has completed, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 48 participants.
The verdict
NCT00027404, a NA study, has completed, sponsored by Icahn School of Medicine at Mount Sinai.
- COMPLETED
- Registry status
- NA
- Development phase
- 48 participants
- Enrollment target
Study Summary
This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.
Interventions
- DRUG Fluoxetine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2001-09 |
| Est. Completion | 2005-08 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00027404
The ClinicalTrials.gov registry entry for NCT00027404 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Fluoxetine is the first listed.
NCT00027404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00027404 about?
NCT00027404 is a clinical study titled "Study of Fluoxetine in Adults With Autistic Disorder". This is a study to determine the effect of fluoxetine in the treatment of adult autism and on functional ability and behavior associated with autism. Evidence suggests abnormal serotonin function in autism. Fluoxetine is a selective inhibitor of the serotonin transporter.
What is the current status of trial NCT00027404?
This trial is currently completed. It is a NA study. The enrollment target is 48 participants. The study started on 2001-09. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00027404?
The interventions under investigation include: Fluoxetine (DRUG).
Who is sponsoring clinical trial NCT00027404?
This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.